155 related articles for article (PubMed ID: 28302493)
1. The risk of second primary cancers due to peripheral photon and neutron doses received during prostate cancer external beam radiation therapy.
Bezak E; Takam R; Yeoh E; Marcu LG
Phys Med; 2017 Oct; 42():253-258. PubMed ID: 28302493
[TBL] [Abstract][Full Text] [Related]
2. Peripheral photon and neutron doses from prostate cancer external beam irradiation.
Bezak E; Takam R; Marcu LG
Radiat Prot Dosimetry; 2015 Dec; 167(4):591-601. PubMed ID: 25564673
[TBL] [Abstract][Full Text] [Related]
3. Out-of-field neutron and leakage photon exposures and the associated risk of second cancers in high-energy photon radiotherapy: current status.
Takam R; Bezak E; Marcu LG; Yeoh E
Radiat Res; 2011 Oct; 176(4):508-20. PubMed ID: 21756083
[TBL] [Abstract][Full Text] [Related]
4. Monte Carlo study of organ doses and related risk for cancer in Algeria from scattered neutrons in prostate treatment involving 3D-CRT.
Alem-Bezoubiri A; Suleiman SA; Behidj I; Mazrou H; Chami AC
Appl Radiat Isot; 2022 Feb; 180():110065. PubMed ID: 34933226
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Photoneutron Dose Measured by Bubble Detectors in Conventional Linacs and Cyberknife Unit: Effective Dose and Secondary Malignancy Risk Estimation.
Biltekin F; Yeginer M; Ozyigit G
Technol Cancer Res Treat; 2016 Aug; 15(4):560-5. PubMed ID: 26152750
[TBL] [Abstract][Full Text] [Related]
6. Constituent components of out-of-field scatter dose for 18-MV intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy: a comparison with 6-MV and implications for carcinogenesis.
Ruben JD; Smith R; Lancaster CM; Haynes M; Jones P; Panettieri V
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):645-53. PubMed ID: 25084609
[TBL] [Abstract][Full Text] [Related]
7. Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy.
Kry SF; Salehpour M; Followill DS; Stovall M; Kuban DA; White RA; Rosen II
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1204-16. PubMed ID: 15990026
[TBL] [Abstract][Full Text] [Related]
8. Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy.
Kry SF; Salehpour M; Titt U; White RA; Stovall M; Followill D
Radiother Oncol; 2009 Apr; 91(1):132-7. PubMed ID: 19147246
[TBL] [Abstract][Full Text] [Related]
9. Special radiobiological features of second cancer risk after particle radiotherapy.
Trott KR
Phys Med; 2017 Oct; 42():221-227. PubMed ID: 29103987
[TBL] [Abstract][Full Text] [Related]
10. Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors.
Berrington de Gonzalez A; Wong J; Kleinerman R; Kim C; Morton L; Bekelman JE
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):295-302. PubMed ID: 25636756
[TBL] [Abstract][Full Text] [Related]
11. Photon neutron mixed-beam radiotherapy of locally advanced prostate cancer.
Haraf DJ; Rubin SJ; Sweeney P; Kuchnir FT; Sutton HG; Chodak GW; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):3-14. PubMed ID: 7642429
[TBL] [Abstract][Full Text] [Related]
12. Peripheral neutron and gamma doses in radiotherapy with an 18 MV linear accelerator.
Vanhavere F; Huyskens D; Struelens L
Radiat Prot Dosimetry; 2004; 110(1-4):607-12. PubMed ID: 15353716
[TBL] [Abstract][Full Text] [Related]
13. Secondary cancer-incidence risk estimates for external radiotherapy and high-dose-rate brachytherapy in cervical cancer: phantom study.
Lee B; Ahn SH; Kim H; Son J; Sung J; Han Y; Huh SJ; Kim JS; Kim DW; Yoon M
J Appl Clin Med Phys; 2016 Sep; 17(5):124-132. PubMed ID: 27685104
[TBL] [Abstract][Full Text] [Related]
14. Measurements of the neutron dose equivalent for various radiation qualities, treatment machines and delivery techniques in radiation therapy.
Hälg RA; Besserer J; Boschung M; Mayer S; Lomax AJ; Schneider U
Phys Med Biol; 2014 May; 59(10):2457-68. PubMed ID: 24778349
[TBL] [Abstract][Full Text] [Related]
15. Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model.
Takam R; Bezak E; Yeoh EE
Phys Med Biol; 2009 Feb; 54(3):611-25. PubMed ID: 19124952
[TBL] [Abstract][Full Text] [Related]
16. MONTE CARLO SIMULATION OF OUT-OF-FIELD ORGAN DOSES AND CANCER RISK IN TANZANIA FOR RADIATION THERAPY OF UNILATERAL RETINOBLASTOMA USING A 60Co UNIT.
Suleiman SA; Qi Y; Pi Y; George Xu X
Radiat Prot Dosimetry; 2018 May; 179(3):263-270. PubMed ID: 29216393
[TBL] [Abstract][Full Text] [Related]
17. Uncomplicated and Cancer-Free Control Probability (UCFCP): A new integral approach to treatment plan optimization in photon radiation therapy.
Sánchez-Nieto B; Romero-Expósito M; Terrón JA; Sánchez-Doblado F
Phys Med; 2017 Oct; 42():277-284. PubMed ID: 28392313
[TBL] [Abstract][Full Text] [Related]
18. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma.
Brodin NP; Munck Af Rosenschöld P; Aznar MC; Kiil-Berthelsen A; Vogelius IR; Nilsson P; Lannering B; Björk-Eriksson T
Acta Oncol; 2011 Aug; 50(6):806-16. PubMed ID: 21767178
[TBL] [Abstract][Full Text] [Related]
19. Risk assessment for cancer induction after low- and high-LET therapeutic irradiation.
Engels H; Menzel HG; Pihet P; Wambersie A
Strahlenther Onkol; 1999 Jun; 175 Suppl 2():47-51. PubMed ID: 10394397
[TBL] [Abstract][Full Text] [Related]
20. Hip stiffness following mixed conformal neutron and photon radiotherapy: a dose-volume relationship.
Chuba PJ; Sharma R; Yudelev M; Duclos M; Shamsa F; Giacalone S; Orton CG; Maughan RL; Forman JD
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):693-9. PubMed ID: 8690635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
